Journal Mobile Options
Table of Contents
Vol. 9, No. 4, 2001
Issue release date: February 2002

Plasma and Cerebrospinal Fluid Interleukin-6 Concentrations in Posttraumatic Stress Disorder

Baker D.G. · Ekhator N.N. · Kasckow J.W. · Hill K.K. · Zoumakis E. · Dashevsky B.A. · Chrousos G.P. · Geracioti Jr. T.D.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Interleukin-6 (IL-6) secretion is suppressed by glucocorticoids and stimulated by catecholamines. Patients with posttraumatic stress disorder (PTSD) have decreased cortisol and increased catecholamine secretion. The purpose of this study was to assess the relation of IL-6 levels and hypothalamic-pituitary-adrenal and noradrenergic activity in patients with well-characterized PTSD. Methods: Cerebrospinal fluid (CSF) was withdrawn via a lumbar subarachnoid catheter over 6 h from 11 combat veterans with PTSD and 8 age- and sex-matched healthy controls. Blood was withdrawn concurrently. We measured IL-6, CRH and norepinephrine concentrations in the CSF and IL-6, ACTH, cortisol and norepinephrine in plasma. Results: Mean and median CSF IL-6 concentrations were higher in PTSD than in controls (mean = 24.0 vs. 14.6, p = 0.05; median = 26.7 vs. 14.3, p < 0.03): plasma IL-6 concentrations, however, were not different between the two groups. Plasma IL-6 and norepinephrine were positively correlated in the PTSD group (r = +0.74, p < 0.04), but not in normals (r = –0.55, p = 0.20). Conclusions: PTSD patients have increased CSF concentrations of IL-6. Their plasma IL-6 is not elevated but is more tightly associated with noradrenergic output in these patients than in normals. Both findings might be explained by the low cortisol secretion previously reported in PTSD as a result of lowered glucocorticoid suppression of IL-6 secretion. High levels of CSF IL-6 may reflect neurodegeneration or compensatory neuroprotection.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Besedovsky HO, Del Rey A: Immune-neuroendocrine circuits: Integrative role of cytokines. Front Neuroendocrinol 1992;13:61–94.
  2. Besedovsky HO, Del Rey A: 1 Immune-neuroendocrine interactions: Facts and hypotheses. Endocr Rev 1996;7:64–102.
  3. Turnbull AV, Rivier C: Regulation of the HPA axis by cytokines. Brain Behav Immun 1995;9:253–275.
  4. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351–1362.
  5. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiological roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–137.
  6. Licinio J, Wong ML: Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997;100:2941–2947.
  7. Berkenbosch F, Van Oers J, Del Rey A, Tilders F, Besedovsky H: Corticotropin-releasing factor producing neurons in the rat activated by interleukin-1. Science 1987;238:524–526.
  8. Sapolsky R, Reivier C, Yamamoto G, Plotsky P, Vale W: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987;238:522–524.
  9. Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S, Mori K, Imura H: Interleukin-6 stimulates the secretion of adrenocorticotropic, freely-moving rats. Biochem Biophys Res Commun 1988;155:1459–1463.
  10. Harbuz MS, Stephanou A, Sarlis N, Lightman SL: The effects of recombinant human interleukin (IL)-1α, IL-1β or IL-6 on hypothalamo-pituitary-adrenal axis activation. J Endocrinol 1992;133:349–355.
  11. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690–1694.
  12. Spath-Schwalbe E, Born J, Schrezenmeier H, Borstein SR, Stromeyer P, Drechsler S, Fehm HL, Prozsolt F: Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994;79:1212–1214.
  13. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Fehm HL, Born J: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573–1579.
  14. Labeur MS, Arzt E, Weigers JG, Holsboer F, Reul JMHM: Long-term intracerebroventricular corticotropin-releasing hormone administration induces distinct changes in rat splenocyte activation and cytokine expression. Endocrinology 1995;136:2678–2688.
  15. Linhorst ACE, Flachskamm C, Hopkins SJ, Hoadley ME, Labeur MS, Holsboer F, Ruel JMHM: Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge. J Neurosci 1997;17:4448–4460.

    External Resources

  16. Arimura A, Takaki A, Komaki G: Interactions between cytokines and the hypothalamic-pituitary-adrenal axis during stress. Ann NY Acad Sci 1994;739:270–281.
  17. Tsigos C, Papanicolaou D, Defensor R, Mitsiadakis CS, Kyrou I, Chrousos GP: Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997;66:54–62.

    External Resources

  18. Papanicolaou D, Tsigos C, Oldfield EH, Chrousos GP: Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Dose the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency. J Clin Endocrinol Metab 1996;81:2303–2306.
  19. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kolagera KTG, Wilder R, Gold PW, Deuster PA, Chrousos GP: Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996;271:E601–E605.

    External Resources

  20. Vallieres L, Rivest S: Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology 1999;140:3890–3903.
  21. Van Gool J, Van Vugt H, Helle M, Aarden LA: The relation among stress, adrenaline, interleukin-6 and acute phase proteins in the rat. Clin Immunol Immunopathol 1990;57:200–210.

    External Resources

  22. DeRijk RH, Boelen A, Tilers FJH, Berkenbosch F: Induction of plasma interleukin-6 by circulating adrenaline in the rat. Psychoneuroendocrinology 1994;19:155–163.
  23. Takaki A, Huang Q, Somogyvari-Vigh A, Arimura A: Immobilization stress may increase plasma interleukin-6 via central and peripheral catecholamines. Neuroimmunomodulation 1994;1:335–342.
  24. Zhou D, Kusnecov AW, Shurin MR, Depaoli M, Rabin BS: Exposure to physical and psychological stressors elevates plasma interleukin 6: Relationship to the activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 1993;133:2523–2530.
  25. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti TD, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW: Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 2000;97:325–330.
  26. Geracioti TD Jr, Loosen PT, Orth DN: Low cerebrospinal fluid corticotropin releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997;42:165–174.
  27. Bremner DJ, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS: Elevated CSF corticotropin-releasing factor concentration in posttraumatic stress disorder. Am J Psychiatry 1997;154:624–629.
  28. Baker DG, West SA, Nicholson SE, Ekhator NN, Bruce AB, Orth DN, Geracioti TD: Serial cerebrospinal fluid corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999;156:585–588.
  29. Geracioti TD, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE, Kasckow JW: Cerebrospinal fluid norepinephrine concentrations in post-traumatic stress disorder. Am J Psychiatry 2001;158:1227–1230.
  30. Licinio J, Wong ML: The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317–327.

    External Resources

  31. Dantzer R, Castanon N, Capuron L, Wollman E: What is the evidence for a role of cytokines in depression (abstract)? Neuroimmunomodulation 2000;8:215.
  32. Bethin KE, Vogt SK, Muglia LJ: Interleukin-6 is an essential, corticotropin releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 2000;97:9317–9322.
  33. Angeli A, Masera RG, Sartori LM, Fortunati N, Racca S, Dovio A, Staurenghi A, Frairia R: Modulation by cytokines of glucocorticoid action. Ann NY Acad Sci 1999;876:210–220.
  34. Finck BN, Dantzer R, Kelley KW, Woods JA, Johnson RW: Central lipolysaccharide elevates plasma IL-6 concentration by an alpha-adrenoreceptor mediated mechanism. Am J Physiol 1997;272:R1880–R1887.

    External Resources

  35. Huang QH, Takaki A, Arimaura A: Central noradrenergic system modulates plasma interleukin-6 production by peripheral interleukin-1. Am J Physiol 1997;272:R731–R738.

    External Resources

  36. Schuld A, Kraus T, Haack M, Hinze-Selch D, Zobel AW, Holsboar F, Pollmacher T: Effects of dexamethasone on cytokine plasma levels and white blood cell counts in depressed patients. Psychoneuroendocrinology 2001:26:65–76.
  37. Song D, Im Y, Jung J, Yan J, Huh S, Suh H, Kim Y: Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amayloid A: Involvement of adrenaline from adrenal medulla. Br J Pharmacol 2000;130:41–48.
  38. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H: Synergistic effects of interleukin-1β, interleukin-6 and tumor necrosis factor-α: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000;22:566–580.
  39. Gornikiewicz A, Sautner T, Brostjan C, Schmierer B, Fugger R, Roth E, Muhlbacher F, Bergmann: Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. FASEB J 2000;14:1093–1100.
  40. Kim HM, Hahn TH: The effect of clonidine pretreatment on the perioperative proinflammatory cytokines, cortisol and ACTH responses in patients undergoing total abdominal hysterectomy. Anesth Analg 2000;90:1441–1444.
  41. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78.
  42. Keller ET, Wanagat J, Erschler WB: Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996;1:d340–d357.

    External Resources

  43. Van Wagoner NJ, Benveniste EN: Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 1999;100:124–139.

    External Resources

  44. May LT, Santhanam U, Tatter SB, Helfgott DC, Ray A, Graeb J, Sehgal PB: Phosphorylation of secreted forms of human β2-interferon/hepatocyte-stimulating factor/interleukin-6. Biochem Biophys Res Commun 1988;152:1144–1150.
  45. Klouche M, Bhakdi S, Hemmes M, Rose-John S: Novel path to activation of vascular smooth muscle cells: Up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999;163:4583–4589.
  46. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. Immunology 1998;161:6347–6355.
  47. Gaillard J, Pugniere M, Tresca J, Mani J, Klein B, Brochier J: Interleukin-6 receptor signaling. II. Bioavailability of interleukin-6 in serum. Eur Cytokine Netw 1996;10:337–343.
  48. Marz P, Cheng JG, Gadient RA, Patterson PH, Stoyan T, Otten U, Rose-John S: Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 1998;95:3251–3256.
  49. Marz P, Heese K, Dimitriades-Schmutz B, Rouse-John S, Otten U: Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999;26:191–200.
  50. Thier M, Marz P, Otten U, Weis J, Rose-John S: Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. J Neurosci Res 1999;55:411–422.
  51. Gao Y, Ng NK, Lina JY, Ling EA: Expression of immunoregulatory cytokines in neurons of the lateral hypothalamic area and amygdaloid nuclear complex of rats immunized against human IgG. Brain Res 2000;859:364–368.

    External Resources

  52. Chen G, McCuskey RS, Reichlin S: Blood interleukin-6 and tumor necrosis factor-alpha elevation after intracerebroventricular injection of Escherichia coli endotoxin in the rat is determined by two opposing factors: Peripheral induction of LPS transferred from brain to blood and inhibition of peripheral response by a brain mediated mechanism. Neuroimmunomodulation 2000;8:59–69.
  53. Reyes TM, Coe CL: Interleukin-1 beta differentially affects interleukin-6 and soluble interleukin-6 receptor in the blood and central nervous system of the monkey. J Neuroimmunol 1996;66:135–141.

    External Resources

  54. Reyes TM, Coe CL: Resistance of central nervous system interleukin-6 to glucocorticoid inhibition in monkeys. Am J Physiol 1998;275:R612–R618.

    External Resources

  55. Yeager MP, Lunt P, Arruda J: Cerebrospinal fluid cytokine levels after surgery or general anesthesia. Reg Anesth Pain Med 1999;24:557–562.
  56. Blatties CM, Quan N, Howell RD: The organum vasculosum laminae terminalis (OVLT) is critical for fever induced in guinea pigs by blood-borne cytokines. Soc Neurosci Abstr 1989;15:718.
  57. Banks WA, Kastin AJ, Gutierrez EG: Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994;179:53–56.
  58. Goehler LE, Gaykema RP, Nguyen KT, Lee JE, Tilders FJ, Maier SF, Watkins LR: Interleukin-1beta in immune cells of the abdominal vagus nerve: A link between the immune and nervous system? J Neurosci 1999;19:2799–2806.
  59. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, Laflamme N: How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000;223:22–38.
  60. Chen G, Castro WI, Chow HH, Reichlin S: Clearance of 125I-labeled interleukin-6 from brain into blood following intracerebroventricular injection in rats. Endocrinology 1997;138:4830–4836.
  61. Borovikova LV, Ivanova S, Zhang MH, Yang H, Botchkina GI, Watkins LR, Wang HC, Abumrad N, Eaton JW, Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–462.
  62. Van Dam AM, Bol JG, Gaykema RP, Goehler LE, Maier SF, Watkins LR, Tiders FJ: Vagotomy does not inhibit high dose lipopolysaccharide-induced interleukin-1beta immunoreactivity in rat brain and pituitary gland. Neurosci Lett 2000;285:169–172.
  63. Maes M, Bosmans E, de Jongh R, Kenis G, Vandoolaeghe E, Neels H: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853–858.
  64. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Reimann D, Berger M: Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Sci 1997;247:228–233.
  65. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatry Res 1996;64:161–167.
  66. Lanquillon S, Kreig JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropharmacology 2000;22:370–379.
  67. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatry Res 1993;33:407–418.
  68. Maes M, Lin Ai-hua, Delmeire L, Van Gastel A, Kenis G, De Johgh R, Bosman E: Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999;45:833–839.
  69. Stubner S, Schon T, Padberg T, Teipel SJ, Schwartz MJ, Haslinger A, Buch K, Dukoff R, Lasser R, Muller N, Sunderland T, Rapoport SI, Moller HJ, Hampel H: Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: No alteration of soluble gp130. Neurosci Lett 1999;259:145–148.
  70. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40:171–176.
  71. Spitzer RL, Williams J: Instructional Manual for the SCID. New York, New York State Psychiatric Institute, 1983.
  72. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Chamey DS, Keane TM: The development of a clinician administered PTSD Scale. J Trauma Stress 1995;8:75–90.
  73. Geracioti TD, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT: Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992;74:1325–1330.
  74. Geracioti TD, Nicholson WE, Orth DN, Ekhator NN, Loosen PT: Cholecystokinin in human cerebrospinal fluid: Concentration, dynamics, molecular forms, and relationship to fasting and feeding in health, depression and alcoholism. Brain Res 1993;692:260–268.
  75. White RJ, Dakters JG, Albin MS: Temporary control of cerebrospinal fluid volume and pressure by means of an externalized valve-drainage system. J Neurosurg 1969;30:264–269.

    External Resources

  76. Nicholson WE, Davis DR, Sherrel BJ, Orth DN: Rapid radioimmunoassay for corticotropin releasing factor. Pharmacol Rev 1991;43:425–473.
  77. Schmidt D, Roznoski M, Ebert MH: Qualitative and quantitative high performance liquid chromatographic analysis of monoamine neurotransmitters and metabolites in cerebrospinal fluid and brain tissue using reductive electrochemical detection. Biomed Chromatogr 1990;4:215–220.
  78. Hayley S, Staines W, Merali Z, Anisman H: Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-alpha. Neuroscience 2001;106:137–148.
  79. Zalcman S, Savina I, Wise RA: Interleukin-6 increases sensitivity to locomotor-stimulating effects of amphetamine in rats. Brain Res 1993;847:275–283.
  80. Merali Z, Lacosta S, Anisman H: Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: A regional microdialysis study. Brain Res 1997;761:225–235.

    External Resources

  81. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H: An assessment of the effects of central interleukin-1β, -2, -6, and tumor necrosis factor-α administration on some behavioral, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998;84:923–933.

    External Resources

  82. Dunn AJ, Wang J, Ando T: Effects of cytokines on cerebral neurotransmission: Comparison with effects of stress. Adv Exp Med Biol 1999;461:117–127.
  83. Fang J, Wang Y, Krueger JM: Effects of interleukin-1 beta on sleep are mediated by the type I receptor. Am J Physiol 1998;274:R655–R660.

    External Resources

  84. Krueger JM, Obal F Jr, Fang J: Humoral regulation of physiological sleep: Cytokines and GHRH. J Sleep Res 1999;8(suppl 11):53–59.
  85. Maier SF, Nguyen KT, Deak T, Milligen ED, Watkins LR: Stress, learned helplessness, and brain interleukin-1 beta. Adv Exp Med Biol 1999;461:235–249.
  86. Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Watkins LR, Maier SF, Watkins LR: Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 1999;106:109–118.
  87. Pugh CR, Johnson FD, Martin D, Rudy JW, Maier SF, Watkins LR: Human immunodeficiency virus-1 coat protein gp 120 impairs contextual fear conditioning: A potential role in AIDS related learning and memory impairments. Brain Res 2000;861:8–15.
  88. Anisman H, Merali Z: Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999;461:199–233.
  89. Anisman H, Ravindran AV, Griffiths J, Merali Z: Endocrine and cytokine corelates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999;4:182–188.
  90. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445–452.
  91. Baker DG, Mendenhall CL, Simbartl LA, Magan LK, Steinberg JL: Relationship between posttraumatic stress disorder and self-reported physical symptoms in Persian gulf war veterans. Arch Intern Med 1997;157:2076–2078.
  92. Shalev A, Bleich A, Ursano RJ: Posttraumatic stress disorder: Somatic comorbidity and effort tolerance. Psychosomatics 1990;31:197–203.
  93. Schnurr PP, Spiro A: Combat exposure, posttraumatic stress disorder symptoms, health behaviors as predictors of self-reported physical health in older veterans. J Nerv Ment Dis 1999;187:353–359.
  94. Mathiesen T, Andersson B, Loftenius A, von Holst H: Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage. J Neurosurg 1993;78:562–567.
  95. Hans VHJ, Kossmann T, Joller H, Otto V, Morganti-Kossmann M: Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport 1999;10:409–412.
  96. Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325–2329.
  97. Peltola J, Palmio J, Korhonen L, Suhonen J, Meittinen A, Hurme M, Lindholm D, Keranen T: Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 2000;41:205–211.

    External Resources

  98. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC: Inflammatory cytokines IL-1α, IL-1β, IL-6, TBF-α impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999;163:3963–3968.
  99. D’Arcangelo G, Tancredi V, Onofri F, D’Antuono M, Giovedi S, Benfenati F: Interleukin-6 inhibits neurotransmitter release and the spread excitation in the rat cerebral cortex. Eur J Neurosci 2000;12:1241–1252.
  100. Muller T, Blum-Degen D, Przuntek H, Kuhn W: Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 1998;98:142–144.
  101. Boscarino JA: Posttraumatic stress disorder, exposure to combat, and lower plasma cortisol among Vietnam veterans: Finding and clinical implications. J Consult Clin Psychol 1996;64:191–201.
  102. Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL, Mason JW: Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis 1990;178:366–369.
  103. Yehuda R, Boisoneau D, Lowy MT, Giller EL: Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. Arch Gen Psychiatry 1995;52:583–593.
  104. Yehuda R, Teicher MH, Trestman RL, Levengood RA, Siever LJ: Cortisol regulation in posttraumatic stress disorder and major depression: A chronobiological analysis. Biol Psychiatry 1996;40:79–88.
  105. Spivak B, Shohat B, Mester R, Avraham S, GilAd I, Bleich A, Valevski A, Weizman A: Elevated levels of serum interleukin-1β in combat-related posttraumatic stress disorder. Biol Psychiatry 1997;42:345–348.
  106. Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, Lis S, Postler E, Voderholzer U, Berger M: Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Invest 1994;72:315.
  107. Sothern RB, Roitman-Johnson B, Kanabrock EL, Yager JG, Fuerstenberg RK, Weatherbee JA, Young MR, Nemchausky BM, Scheving LE: Circadian characteristics of interleukin-6 in blood and urine of clinically healthy men. In Vivo 1995;9:331–339.
  108. Born J, Lange T, Hansen K, Molle M, Fehm H: Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997;158:4454–4464.
  109. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279–1283.
  110. Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F: Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992;242:53–56.
  111. Kanabrocki EL, Sothern RB, Messmore HL, Roitman-Johnson B, McCormick JB, Dawson S, Bremner FW, Third JLHC, Nemchausky BA, Shirazi P, Scheving LE: Circadian interrelationships among levels of plasma fibrinogen platelets, and serum interleukin-6. Clin Appl Thromb Hemost 1999;5:37–42.
  112. Lissoni P, Rovelli F, Brivio F, Brivio O, Fumagalli L: Circadian secretions of IL-2, IL-12, IL-6, and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat Immun 1998;16:1–5.
  113. Petrovsky N, Harison LC, McNair P: Diurnal rhythms of pro-inflammatory cytokines: Regulation of plasma cortisol and therapeutic implications. Cytokine 1998;10:307–312.
  114. Redwine L, Hauger RL, Gillin JC, Irwin M: Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Endocrinol Metab 1985;10:3597–3603.
  115. Cava F, Gonzalez C, Pascual MJ, Mavajo JA, Gonzalez-Buitrago JM: Biological variation of interleukin 6 (IL-6) and soluble interleukin 2 receptor (sIL2R) in serum of healthy individuals. Cytokine 2000;12:1423–1425.

    External Resources

  116. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmacher T: Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000;12:694–698.

    External Resources

  117. Natelson BH, Denny T, Zhou XD, LaManca JJ, Ottenweller JE, Tiersky L, DeLuca J, Gause WC: Is depression associated with immune activation? J Affect Disord 1999;53:179–184.
  118. Wei J, Xu H, Davies JL, Hemmings GP: Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992;51:1953–1956.
  119. Daynes RA, Araneo BA, Ershler WB, Ershler C, Maloney C, Li GZ, Ryu Y: Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993;150:5219–5230.
  120. Dugue B, Leppanen E: Short-term variability in the concentration of serum interleukin-6 and its soluble receptor in subjectively healthy persons. Clin Chem Lab Med 1998;36:323–325.
  121. Ershler WB, Keller ET: Age-associated increased interleukin-6, gene expression, late-life diseases, and frailty. Annu Rev Med 2000;51:245–270.
  122. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–3342.
  123. Vgontzas AN, Bixler EO, Papanicolaou DA, Kales A, Stratakis CA, Vela-Bueno A, Gold PW, Chrousos GP: Rapid eye movement sleep correlates with the overall activities of the hypothalamic-pituitary-adrenal axis and sympathetic system in healthy humans. J Clin Endocrinol Metab 1997;82:3278–3280.
  124. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin H, Kales A, Chrousos GP: Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–1158.
  125. Vgontzas AN, Bixler EO, Papanicolaou DA, Chrousos GP: Chronic systemic inflammation in overweight and obese adults (letter). JAMA 2000;283:2235.
  126. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP: The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999;84:2126–2133.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50